Jiangsu Hengrui Pharmaceuticals Co., Ltd.
10% Owner
Company
- 2026
- Aug 10, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jiangsu Hengrui Pharmaceuticals Co., Ltd. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Forbion Growth Opportunities Fund III Cooperatief U.A. - $64.80M in BRVE purchases and sales in the last 12 months
- ORBIMED ADVISORS LLC - $34.92M in BRVE purchases and sales in the last 12 months
- Erez Chimovits - $34.92M in BRVE purchases and sales in the last 12 months
- AH Bio Fund IV, L.P. - $19.80M in BRVE purchases and sales in the last 12 months
- Christopher Viehbacher - $1.50M in BRVE purchases and sales in the last 12 months
- Travis Murdoch - $1.50M in BRVE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd.?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a corporate entity, tracked as 10% Owner of Braveheart Bio, Inc. (BRVE). InsiderAlpha holds 2 primary Form 4 filings for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jiangsu Hengrui Pharmaceuticals Co., Ltd. submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
